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depth in a single fraction delivered with cylindrical shaped 
flat applicators attached to a 50kV x-ray energy source 
(INTRABEAM). The flat applicator (sizes 3-6cm) was placed at 
the high-risk area within the surgical cavity, which was 
delineated by the surgeon as the area with high likelihood for 
close or positive margins. The average IORT delivery time was 
20 minutes. The single IORT fraction was the sole treatment 
for all patients with recurrent, previously treated patients 
and in one patient with parotid tumors, while the remaining 
six patients with parotid malignancies received additional 
external beam radiotherapy(EBRT) (median dose 50Gy) four 
weeks after surgery. Decision for EBRT were based on review 
of final pathology. 
 
Results: All patients underwent successful completion of 
intraoperative radiotherapy. With follow up time of 5 to 18 
months, there have been no acute side effects or 
complications related to IORT. All patients with parotid 
tumors are currently NED; in patients with recurrent tumors, 
1 of 5 has re-recurred. 
 
Conclusion: IORT with low kv x-rays appears to be an 
excellent choice for selected patients with H&N cancers, 
both primary(parotid) and recurrent disease.  
We are now in the process of initiating a prospective trial 
evaluating the use of IORT as part of primary management of 
parotid tumors at our institution.  
Detailed results will be presented. 
 
Corresponding author: 
Emami, M.D, FACR, FASTRO Professor  
Dept. of Radiation Oncology  
Loyola University 
 
EP-1047  
Volume, FDG-PET and ADC responses could predict a 
similar prognostic benefit as HPV status 
Z. Gouw
1Netherlands Cancer Institute Antoni van Leeuwenhoek 
Hospital, Department of Radiation Oncology, Amsterdam, 
The Netherlands 
1, M. La Fontaine1, O. Hamming-Vrieze1, A. Al-
Mamgani1, P. Van Houdt1, J.J. Sonke1 
 
Purpose or Objective: Patients treated with concurrent 
chemoradiation (CCRT) for head and neck cancer (HNC) with 
HPV(+) associated tumours have a significantly better 
prognosis compared to those with HPV(-) tumours. Similarly, 
better prognosis was associated with changes during-
treatment consisting of either a reduction in tumour volume, 
or FDG-PET SUV, or an increase in ADC. This study 
investigated a possible association between these imaging 
biomarkers and HPV status. Our hypothesis was that HPV(+) 
tumours show a stronger ADC increase and a larger volume 
and SUV decrease. 
 
Material and Methods: 13 Patients with HNC stadium III-IVA 
underwent CCRT (11 oropharynx, 1 hypopharynx and 1 oral 
cavity). HPV status was assessed using P16 staining. Patients 
received FDG-PET and MRI imaging before the start of the 
treatment and at the end of the second week. The region of 
interest consisted of the GTV and was delineated by 
dedicated radiation-oncologists. The volume and the median 
SUV and ADC were measured pretreatment and during 
treatment. Relative responses were calculated by subtracting 
the pretreatment from the during treatment value, which 
was then normalized to the pretreatment value. A new 
variable (pooled response) was computed consisting of the 
average of the relative SUV and volume decrease and ADC 
increase. A one tailed independent samples t-test compared 
the average responses between the HPV(+) and HPV(-) 
tumours. Voxel-based Pearson correlation coefficients 
between baseline and response maps were calculated for ADC 
and FDG-PET. A Fisher’s z-transformation was used to 
compare the correlation coefficients between HPV(+) and 
HPV(-) tumours. 
 
Results: 7 out of 13 tumours were HPV(+) and 6 HPV(-). 
Comparing HPV(+) to HPV(-), GTV volume decreased 42% vs 
28% (p=0.080), SUV decreased with 32% vs 5% for (p=0.074) 
and ADC increased 24% vs 7% (p=0.058) (figure 1). The total 
response was significantly higher for HPV(+) tumours (33% vs 
13%, p=0.012). Correlation coefficients between baseline and 
response maps did not differ significantly for HPV(+) and 
HPV(-) tumours (PET: z= 1.05 vs 1.08 p=0.85, ADC: z=0.47 vs 
0.51, p=0.78). 
 
Conclusion: Volume, ADC and FDG-PET individually showed a 
trend towards a higher response in the HPV(+) tumours at the 
end of the second week CCRT. The total response was 
significantly higher for HPV(+) tumours, demonstrating a 
significant association between HPV-status and imaging 
biomarkers. The similar correlation coefficients of the 
response maps indicate the spatial distribution does not 
depend on HPV status. This study emphasises the importance 
of reporting HPV status in imaging response biomarker studies 
for HNC patients. A validation of the prognostic value of 
imaging response biomarkers within HPV(+) and (-) cohorts is 
warranted. 
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Purpose or Objective: MTL005 is a novel metalloporphyrin 
that demonstrated efficacy as a radiosensitizer in oxic and 
hypoxic pre-clinical models, increasing tumour doubling times 
by 50-90% depending on radiation dose. MTL005 achieved 
higher concentrations in tumour tissue compared with normal 
tissues (6:1 ratio), and these higher levels were retained for 
up to 62 days post administration. We developed a first-in-
human phase I, open label, dose escalation, multicenter 
clinical trial to evaluate the safety and tolerability of single 
dose MTL005 in combination with radiotherapy (Part 1) and 
cisplatin chemo-radiotherapy (Part 2) in patients with locally 
advanced head & neck cancer treated with palliative and 
curative intent respectively. The results of Part 1 of the 
study are reported. 
 
Material and Methods: In Part 1 of the study MTL005 was 
administered 1 week prior to palliative radiotherapy as i.v. 
injection in 38-76 minutes. Two dose levels were explored (2 
and 4 mg/kg). Patients were immobilised in a thermoplastic 
mask and a contrast enhanced CT scan was used to define the 
PTV and the organs at risk. Radiotherapy was delivered with 
IMRT with a total dose of 50Gy to the PTV in 25 consecutive 
